All news articles for January 2021

© GettyImages/AmyKerk

Pfizer backing biotechnology innovation with $120m capital outlay

By Jane Byrne

Pfizer is investing US$25m in a US developer of live biotherapeutics, Vedanta Biosciences; that project is one of four investments, totaling US$120m, made by Pfizer in the second half of 2020 under its breakthrough growth program focused on clinical stage...

Pic:getty/gajus

Sanofi to acquire Kymab for up to $1.45bn

By Rachel Arthur

Sanofi will acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies. The acquisition will give it global rights to KY1005, which has the potential to treat a range of immune-mediated diseases and inflammatory...

Follow us

Products

View more

Webinars